STOCK TITAN

[144] Takeda Pharmaceutical Company Limited American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating a proposed sale of restricted securities.

  • Securities to be sold: 4,477 American Depositary Shares (ADSs).
  • Estimated market value: US $69,035.34.
  • Broker: Interactive Brokers LLC, Greenwich, CT.
  • Approximate sale date: 9 July 2025 on the NYSE.
  • Shares outstanding: 123,490,548 ADSs – the planned sale represents less than 0.01% of this total.
  • Source of shares: Vested Restricted Stock Unit (RSU) awards acquired 1 July 2025 as compensation from Takeda Pharmaceutical Company Limited.
  • Prior sales: None reported in the past three months.

The filing is routine and does not include earnings data or announce any strategic transactions. It simply registers a modest insider sale that is immaterial relative to the company’s share base.

Takeda Pharmaceutical Company Limited (TAK) ha presentato un Modulo 144 che indica una proposta di vendita di titoli soggetti a restrizioni.

  • Titoli da vendere: 4.477 American Depositary Shares (ADS).
  • Valore di mercato stimato: 69.035,34 USD.
  • Intermediario: Interactive Brokers LLC, Greenwich, CT.
  • Data approssimativa di vendita: 9 luglio 2025 alla NYSE.
  • Azioni in circolazione: 123.490.548 ADS – la vendita prevista rappresenta meno dello 0,01% del totale.
  • Origine delle azioni: Premi in Restricted Stock Unit (RSU) maturati il 1° luglio 2025 come compenso da Takeda Pharmaceutical Company Limited.
  • Vendite precedenti: Nessuna segnalata negli ultimi tre mesi.

La comunicazione è di routine e non include dati sugli utili né annuncia operazioni strategiche. Si tratta semplicemente della registrazione di una modesta vendita da parte di un insider, irrilevante rispetto al totale delle azioni della società.

Takeda Pharmaceutical Company Limited (TAK) ha presentado un Formulario 144 que indica una propuesta de venta de valores restringidos.

  • Valores a vender: 4.477 American Depositary Shares (ADS).
  • Valor estimado en mercado: 69.035,34 USD.
  • Corredor: Interactive Brokers LLC, Greenwich, CT.
  • Fecha aproximada de venta: 9 de julio de 2025 en la NYSE.
  • Acciones en circulación: 123.490.548 ADS – la venta planeada representa menos del 0,01% del total.
  • Origen de las acciones: Premios en Restricted Stock Unit (RSU) adquiridos el 1 de julio de 2025 como compensación de Takeda Pharmaceutical Company Limited.
  • Ventas previas: Ninguna reportada en los últimos tres meses.

La presentación es rutinaria y no incluye datos de ganancias ni anuncia transacciones estratégicas. Simplemente registra una modesta venta interna que es insignificante en relación con la base total de acciones de la compañía.

Takeda Pharmaceutical Company Limited (TAK)은 제한된 증권의 매각을 제안하는 Form 144를 제출했습니다.

  • 매도 예정 증권: 4,477 미국 예탁증서(ADS).
  • 추정 시장 가치: 미화 69,035.34달러.
  • 중개인: Interactive Brokers LLC, Greenwich, CT.
  • 예상 매각일: 2025년 7월 9일 NYSE에서.
  • 발행 주식 수: 123,490,548 ADS – 예정된 매각은 전체의 0.01% 미만에 해당합니다.
  • 주식 출처: 2025년 7월 1일에 Takeda Pharmaceutical Company Limited로부터 보상으로 취득한 권리 확정 Restricted Stock Unit (RSU) 상여금.
  • 최근 3개월 내 매도 내역: 보고된 바 없음.

이번 제출은 정기적인 절차로, 수익 데이터나 전략적 거래 발표를 포함하지 않습니다. 단지 회사 주식 총수에 비해 미미한 내부자 매도를 등록한 것입니다.

Takeda Pharmaceutical Company Limited (TAK) a déposé un Formulaire 144 indiquant une proposition de vente de titres restreints.

  • Titres à vendre : 4 477 American Depositary Shares (ADS).
  • Valeur marchande estimée : 69 035,34 USD.
  • Intermédiaire : Interactive Brokers LLC, Greenwich, CT.
  • Date approximative de vente : 9 juillet 2025 à la NYSE.
  • Actions en circulation : 123 490 548 ADS – la vente prévue représente moins de 0,01 % de ce total.
  • Origine des actions : Attributions de Restricted Stock Units (RSU) acquises le 1er juillet 2025 en tant que rémunération de Takeda Pharmaceutical Company Limited.
  • Ventes antérieures : Aucune déclarée au cours des trois derniers mois.

Le dépôt est de routine et n'inclut pas de données sur les bénéfices ni n'annonce de transactions stratégiques. Il s'agit simplement de l'enregistrement d'une modeste vente par un initié, insignifiante par rapport à la base totale d'actions de la société.

Takeda Pharmaceutical Company Limited (TAK) hat ein Formular 144 eingereicht, das einen geplanten Verkauf von eingeschränkten Wertpapieren anzeigt.

  • Zu verkaufende Wertpapiere: 4.477 American Depositary Shares (ADS).
  • Geschätzter Marktwert: 69.035,34 USD.
  • Broker: Interactive Brokers LLC, Greenwich, CT.
  • Ungefähres Verkaufsdatum: 9. Juli 2025 an der NYSE.
  • Ausstehende Aktien: 123.490.548 ADS – der geplante Verkauf entspricht weniger als 0,01 % davon.
  • Quelle der Aktien: Vested Restricted Stock Unit (RSU)-Zuwendungen, erworben am 1. Juli 2025 als Vergütung von Takeda Pharmaceutical Company Limited.
  • Vorherige Verkäufe: In den letzten drei Monaten keine gemeldet.

Die Meldung ist routinemäßig und enthält keine Gewinnzahlen oder Ankündigungen strategischer Transaktionen. Es handelt sich lediglich um die Registrierung eines unbedeutenden Insider-Verkaufs, der im Verhältnis zum Aktienbestand des Unternehmens unerheblich ist.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small insider Form 144 for 4,477 ADSs (US$69k) is routine and immaterial; no strategic signal for TAK investors.

The notice covers a proposed sale amounting to roughly 0.004% of Takeda’s ADS float. Such filings are common for employees or executives monetising vested RSUs. The aggregate value is negligible for a US$50 billion-plus market-cap company and does not alter supply–demand dynamics. No adverse information is asserted in the certification, and no additional sales have occurred in the prior quarter. I view the disclosure as non-impactful to the investment thesis or valuation.

Takeda Pharmaceutical Company Limited (TAK) ha presentato un Modulo 144 che indica una proposta di vendita di titoli soggetti a restrizioni.

  • Titoli da vendere: 4.477 American Depositary Shares (ADS).
  • Valore di mercato stimato: 69.035,34 USD.
  • Intermediario: Interactive Brokers LLC, Greenwich, CT.
  • Data approssimativa di vendita: 9 luglio 2025 alla NYSE.
  • Azioni in circolazione: 123.490.548 ADS – la vendita prevista rappresenta meno dello 0,01% del totale.
  • Origine delle azioni: Premi in Restricted Stock Unit (RSU) maturati il 1° luglio 2025 come compenso da Takeda Pharmaceutical Company Limited.
  • Vendite precedenti: Nessuna segnalata negli ultimi tre mesi.

La comunicazione è di routine e non include dati sugli utili né annuncia operazioni strategiche. Si tratta semplicemente della registrazione di una modesta vendita da parte di un insider, irrilevante rispetto al totale delle azioni della società.

Takeda Pharmaceutical Company Limited (TAK) ha presentado un Formulario 144 que indica una propuesta de venta de valores restringidos.

  • Valores a vender: 4.477 American Depositary Shares (ADS).
  • Valor estimado en mercado: 69.035,34 USD.
  • Corredor: Interactive Brokers LLC, Greenwich, CT.
  • Fecha aproximada de venta: 9 de julio de 2025 en la NYSE.
  • Acciones en circulación: 123.490.548 ADS – la venta planeada representa menos del 0,01% del total.
  • Origen de las acciones: Premios en Restricted Stock Unit (RSU) adquiridos el 1 de julio de 2025 como compensación de Takeda Pharmaceutical Company Limited.
  • Ventas previas: Ninguna reportada en los últimos tres meses.

La presentación es rutinaria y no incluye datos de ganancias ni anuncia transacciones estratégicas. Simplemente registra una modesta venta interna que es insignificante en relación con la base total de acciones de la compañía.

Takeda Pharmaceutical Company Limited (TAK)은 제한된 증권의 매각을 제안하는 Form 144를 제출했습니다.

  • 매도 예정 증권: 4,477 미국 예탁증서(ADS).
  • 추정 시장 가치: 미화 69,035.34달러.
  • 중개인: Interactive Brokers LLC, Greenwich, CT.
  • 예상 매각일: 2025년 7월 9일 NYSE에서.
  • 발행 주식 수: 123,490,548 ADS – 예정된 매각은 전체의 0.01% 미만에 해당합니다.
  • 주식 출처: 2025년 7월 1일에 Takeda Pharmaceutical Company Limited로부터 보상으로 취득한 권리 확정 Restricted Stock Unit (RSU) 상여금.
  • 최근 3개월 내 매도 내역: 보고된 바 없음.

이번 제출은 정기적인 절차로, 수익 데이터나 전략적 거래 발표를 포함하지 않습니다. 단지 회사 주식 총수에 비해 미미한 내부자 매도를 등록한 것입니다.

Takeda Pharmaceutical Company Limited (TAK) a déposé un Formulaire 144 indiquant une proposition de vente de titres restreints.

  • Titres à vendre : 4 477 American Depositary Shares (ADS).
  • Valeur marchande estimée : 69 035,34 USD.
  • Intermédiaire : Interactive Brokers LLC, Greenwich, CT.
  • Date approximative de vente : 9 juillet 2025 à la NYSE.
  • Actions en circulation : 123 490 548 ADS – la vente prévue représente moins de 0,01 % de ce total.
  • Origine des actions : Attributions de Restricted Stock Units (RSU) acquises le 1er juillet 2025 en tant que rémunération de Takeda Pharmaceutical Company Limited.
  • Ventes antérieures : Aucune déclarée au cours des trois derniers mois.

Le dépôt est de routine et n'inclut pas de données sur les bénéfices ni n'annonce de transactions stratégiques. Il s'agit simplement de l'enregistrement d'une modeste vente par un initié, insignifiante par rapport à la base totale d'actions de la société.

Takeda Pharmaceutical Company Limited (TAK) hat ein Formular 144 eingereicht, das einen geplanten Verkauf von eingeschränkten Wertpapieren anzeigt.

  • Zu verkaufende Wertpapiere: 4.477 American Depositary Shares (ADS).
  • Geschätzter Marktwert: 69.035,34 USD.
  • Broker: Interactive Brokers LLC, Greenwich, CT.
  • Ungefähres Verkaufsdatum: 9. Juli 2025 an der NYSE.
  • Ausstehende Aktien: 123.490.548 ADS – der geplante Verkauf entspricht weniger als 0,01 % davon.
  • Quelle der Aktien: Vested Restricted Stock Unit (RSU)-Zuwendungen, erworben am 1. Juli 2025 als Vergütung von Takeda Pharmaceutical Company Limited.
  • Vorherige Verkäufe: In den letzten drei Monaten keine gemeldet.

Die Meldung ist routinemäßig und enthält keine Gewinnzahlen oder Ankündigungen strategischer Transaktionen. Es handelt sich lediglich um die Registrierung eines unbedeutenden Insider-Verkaufs, der im Verhältnis zum Aktienbestand des Unternehmens unerheblich ist.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many Takeda (TAK) ADSs are being sold under this Form 144?

The filing covers 4,477 ADSs.

What is the approximate market value of the proposed TAK share sale?

The aggregate market value is US$69,035.34.

When is the expected sale date for the Takeda ADSs?

The filer plans to sell on or about 9 July 2025.

What percentage of Takeda’s outstanding ADSs does this sale represent?

Less than 0.01% of the 123,490,548 ADSs outstanding.

Where will the TAK ADSs be sold and through which broker?

They are slated for sale on the NYSE via Interactive Brokers LLC.
Takeda Pharm

NYSE:TAK

TAK Rankings

TAK Latest News

TAK Latest SEC Filings

TAK Stock Data

46.87B
3.16B
0.01%
2.33%
0.14%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo